RSL1D1

Across TCGA pan-cancer cohorts, RSL1D1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RSL1D1 data layer compared with 26 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher RSL1D1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RSL1D1 expression acts as an unfavorable survival marker.

LUSC, LIHC, and COAD are the cancer types where RSL1D1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.079	0.792	<.001	36	view →
LIHC	DFS	Median	All	0.040	0.553	<.001	18	view →
COAD	OS	Median	III,IV	0.177	0.694	.005	15	view →
SKCM	OS	Median	All	0.450	0.782	.016	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RSL1D1–LUSC (DFS)

Open the LUSC breakdown →